Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

No. 49 / 2024Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across ...

or for maintenance post-GLP-1 cessation,” said Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences. “Additionally, we are excited to introduce three new programs ...

The BIO-Europe conference provides a prestigious platform for Tiziana to highlight its strategic advancements to the biopharma community, as well as to expand its partnerships aimed at accelerating ...

Eli Lilly's product pipeline is anchored by its GLP-1 receptor agonists, Mounjaro (tirzepatide) and Zepbound. These drugs have shown impressive results in treating type 2 diabetes and obesity, ...

While Novo Nordisk currently dominates the GLP-1 industry, a number of other players are looking to enter the space. Viking has several drug candidates in its pipeline. But the one that investors ...